May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Use of Loteprednol to Control Immune Stromal Keratitis Secondary to Herpes Simplex Virus
Author Affiliations & Notes
  • K.E. Taba
    Internal Medicine, Methodist University Hospital, Memphis, TN, United States
  • M.A. Malecha
    Ophthalmology, University of Tennessee, Memphis, TN, United States
  • S. Schuman
    Ophthalmology, University of Tennessee, Memphis, TN, United States
  • Footnotes
    Commercial Relationships  K.E. Taba, None; M.A. Malecha, None; S. Schuman, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4759. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K.E. Taba, M.A. Malecha, S. Schuman; Use of Loteprednol to Control Immune Stromal Keratitis Secondary to Herpes Simplex Virus . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4759.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: We believe the use of a topical steroid - loteprednol to treat herpes simplex keratitis (HSV) has not been reported. The presumed advantages of loteprednol would be a low risk of intraocular pressure elevation and a low risk of cataract formation. We report the efficacy of loteprednol in controlling immune stromal keratitis (ISK) secondary to HSV in a group of patients. Methods: We retrospectively reviewed the records of all patients with ISK secondary to HSV treated with loteprednol in the University of Tennessee Department of Ophthalmology between August 2000 and August 2002 for duration of treatment, number of recurrences of ISK, final visual acuity, and side effects of the therapy. Results: Seven patients diagnosed with ISK secondary to HSV were treated with either loteprednol 0.5% or loteprednol 0.2%, dosed from 1 to 4 times daily. Oral acyclovir was prescribed along with loteprednol in 6 out of 7 cases. The mean age of the patients was 32 years (range, 5-60 years). The mean follow-up after beginning the therapy with loteprednol was 10 months (range, 6-20 months). Four patients experienced a recurrence of ISK while on loteprednol which resolved in all cases with an increase in dosage of loteprednol. No elevations of intraocular pressure were observed with loteprednol except in one patient who had a concurrent diagnosis of primary open angle glaucoma. One patient developed an infectious epithelial keratitis secondary to HSV while on loteprednol which necessitated discontinuation of the loteprednol. None of the patients developed a cataract while on loteprednol. The mean final visual acuity was 20/30 and was unchanged from the mean initial visual acuity. Conclusions: Loteprednol is an effective treatment of ISK secondary to HSV. Use of loteprednol in ISK is associated with a low incidence of side effects, such as elevations in intraocular pressure, formation of cataracts, or reactivation of infectious epithelial keratitis.

Keywords: herpes simplex virus • clinical (human) or epidemiologic studies: tre • pharmacology 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.